Madina Agénor1, Heather L McCauley2, Sarah M Peitzmeier3, Sebastien Haneuse4, Allegra R Gordon5, Jennifer Potter6, S Bryn Austin7. 1. Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Center for Community-Based Research, Dana Farber Cancer Institute, Boston, Massachusetts. Electronic address: magenor@mail.harvard.edu. 2. Division of Adolescent Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; Division of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 5. Division of Adolescent and Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts. 6. Department of Medicine, Harvard Medical School, Boston, Massachusetts; Women's Health Program, Fenway Health, Boston, Massachusetts; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 7. Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Division of Adolescent and Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Abstract
INTRODUCTION: Girls and women are at risk of human papillomavirus (HPV) infection and cervical cancer from male and female sexual partners throughout the life course. However, no study has assessed how sex of sexual partners, a dimension of sexual orientation, may relate to HPV vaccination among girls and women. METHODS: In 2014, data from the 2006-2010 National Survey of Family Growth were used to conduct logistic regression analyses estimating the relationship between sex of lifetime and past-year sexual partners and HPV vaccine awareness and initiation among U.S. girls and women aged 15-25 years (N=3,253). RESULTS: Among U.S. girls and women aged 15-25 years, the prevalence of HPV vaccine awareness and HPV vaccine initiation was 84.4% and 28.5%, respectively. Adjusting for sociodemographic factors, participants with only female past-year sexual partners had significantly lower odds of initiating HPV vaccination relative to those with only male past-year sexual partners (OR=0.16, 95% CI=0.05, 0.55). Similarly, respondents with no lifetime (OR=0.65, 95% CI=0.46, 0.92) or past-year (OR=0.69, 95% CI=0.50, 0.94) sexual partners had significantly lower adjusted odds of HPV vaccine initiation compared with those with only male sexual partners. No difference was apparent in the odds of initiating HPV vaccination between participants with male and female sexual partners and those with only male sexual partners. CONCLUSIONS: Medical and public health professionals should ensure that girls and women with only female or no sexual partners are included in HPV vaccine education and promotion efforts.
INTRODUCTION:Girls and women are at risk of human papillomavirus (HPV) infection and cervical cancer from male and female sexual partners throughout the life course. However, no study has assessed how sex of sexual partners, a dimension of sexual orientation, may relate to HPV vaccination among girls and women. METHODS: In 2014, data from the 2006-2010 National Survey of Family Growth were used to conduct logistic regression analyses estimating the relationship between sex of lifetime and past-year sexual partners and HPV vaccine awareness and initiation among U.S. girls and women aged 15-25 years (N=3,253). RESULTS: Among U.S. girls and women aged 15-25 years, the prevalence of HPV vaccine awareness and HPV vaccine initiation was 84.4% and 28.5%, respectively. Adjusting for sociodemographic factors, participants with only female past-year sexual partners had significantly lower odds of initiating HPV vaccination relative to those with only male past-year sexual partners (OR=0.16, 95% CI=0.05, 0.55). Similarly, respondents with no lifetime (OR=0.65, 95% CI=0.46, 0.92) or past-year (OR=0.69, 95% CI=0.50, 0.94) sexual partners had significantly lower adjusted odds of HPV vaccine initiation compared with those with only male sexual partners. No difference was apparent in the odds of initiating HPV vaccination between participants with male and female sexual partners and those with only male sexual partners. CONCLUSIONS: Medical and public health professionals should ensure that girls and women with only female or no sexual partners are included in HPV vaccine education and promotion efforts.
Authors: James M Lepkowski; William D Mosher; Karen E Davis; Robert M Groves; John van Hoewyk; Jennifer Willem Journal: Vital Health Stat 2 Date: 2006-07
Authors: Madina Agénor; Sarah Peitzmeier; Allegra R Gordon; Sebastien Haneuse; Jennifer E Potter; S Bryn Austin Journal: Ann Intern Med Date: 2015-07-21 Impact factor: 25.391
Authors: Ilana B Addis; Stephen K Van Den Eeden; Christina L Wassel-Fyr; Eric Vittinghoff; Jeanette S Brown; David H Thom Journal: Obstet Gynecol Date: 2006-04 Impact factor: 7.661
Authors: Eric Adjei Boakye; Nosayaba Osazuwa-Peters; Julia López; Vy T Pham; Betelihem B Tobo; Leping Wan; Mario Schootman; Jane A McElroy Journal: Hum Vaccin Immunother Date: 2020-07-23 Impact factor: 3.452
Authors: Brittany M Charlton; Sari L Reisner; Madina Agénor; Allegra R Gordon; Vishnudas Sarda; S Bryn Austin Journal: LGBT Health Date: 2017-05-03 Impact factor: 4.151
Authors: Madina Agénor; Sarah M Peitzmeier; Allegra R Gordon; Brittany M Charlton; Sebastien Haneuse; Jennifer Potter; S Bryn Austin Journal: Cancer Causes Control Date: 2016-08-09 Impact factor: 2.506